Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
D360 User Group Meeting Hailed as “Highly Informative and Incredibly Valuable”
October 17, 2014
User Group Meeting "Highly Informative and Incredibly Valuable," Says D360 Clients
ST. LOUIS, MO – Oct. 17, 2014 – Certara’s Second Annual D360™ User Group Meeting (UGM) was described as “Highly Informative” and “Incredibly Valuable” by top pharmaceutical scientists who attended. The meeting, held at the Boston’s Royal Sonesta Hotel on October 8 and 9, 2014, was attended by representatives from more than 80% of D360’s client organizations from across the US and Europe. “The success of the meeting was a direct result of the open sharing of user experiences through presentations and networking,” said Dr. David Lowis, Certara’s Sr. Director, Product Management and organizer of the event. Dr. Lowis added, “The 2014 meeting more than doubled last year's attendance numbers to over 65 attendees, mirroring the strong growth in the D360 user base for scientific data analytics in both discovery and nonclinical development.”
Thirteen client speakers from organizations like Pfizer, Agios, Sanofi, Celgene, Medivir, Biogen Idec, Boehringer Ingelheim and AstraZeneca, to name a few, described how D360 provided value in addressing scientific and informatics challenges and implementing best practices. Presentations covered a number of topics relevant to the general scientific community:
- Selecting the right tool set for data access and analysis
- The importance of self-service data analytics and refocusing IT on high value tasks
- Rapid access & analysis of preclinical data for real-time study monitoring and safety-exposure relationship development.
- Successful strategies for rapid D360 deployment and adoption.
- Best practices in scientific business intelligence from user and technical perspectives.
Dr. Lowis also shared the company’s D360 strategy with these key clients, as a roadmap for maintaining and growing the company’s industry leading position. “Our annual D360 UGM is one of the most effective ways we incorporate customer feedback into the future direction of D360,“ Lowis said. “Having an open forum where the diversity of ways D360 provides scientific value is exposed is key to our science guided product strategy and development of value for our customers, we anticipate the 2015 event to double in attendance again.”
The D360 user community draws from a wide range of organizations of different users from different disciplines. “Our top priority is to ensure that D360 allows all our customers’ scientific research to be inherently driven by available experimental and predictive data,” said Jonathan Feldmann, Certara’s Chief Technology Officer.
About Certara
Certara is the leading technology-enabled drug development and drug safety consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.
For Further Information
Certara Contact:
Teresa A. Bradford, 919-852-4644
Senior Director, Marketing
Teresa.Bradford@certara.com
Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com